Faries Douglas E, Ascher-Svanum Haya, Nyhuis Allen W, Kinon Bruce J
Eli Lilly & Co., Lilly Research Laboratories, Indianapolis, IN 46285, USA.
Curr Med Res Opin. 2008 May;24(5):1399-405. doi: 10.1185/030079908x297385. Epub 2008 Apr 7.
Switching medications is common in the treatment of schizophrenia. This study examines the effectiveness of olanzapine therapy following a clinically warranted switch from risperidone during treatment of patients with schizophrenia.
This post-hoc analysis used data from the risperidone arm of a randomized, open-label, 1-year study of patients with schizophrenia. Study protocol permitted antipsychotic switching when clinically warranted, and outcomes were assessed with standard psychiatric measures. Statistical analyses assessed changes from pre- to post-medication switch and endpoint comparisons between patients switched from risperidone to olanzapine and patients continued on risperidone.
Most patients who switched from risperidone switched to olanzapine (43/60; 71.7%). Average duration of risperidone treatment prior to switching was 86 days (mean modal dose 4.0 mg/day). Most switchers (86%) completed the 1-year study on olanzapine (average duration 241 days; mean modal dose 12.0 mg/day). Following switch to olanzapine, patients experienced significant improvements on clinical (Brief Psychiatric Rating Scale) and social (Quality of Life Inventory) parameters, with similar proportions of patients achieving remission status at endpoint compared with risperidone patients not requiring medication switch (41.9 vs. 35.5%). Mean weight gain for switchers was approximately 0.4 kg while on risperidone (average treatment duration < 3 months) and 2.4 kg on olanzapine (average treatment duration approximately 8 months).
This study suggests that olanzapine is an effective treatment option for schizophrenia patients requiring a switch from risperidone. Given the small sample size and lack of a comparative group, one cannot determine if other medication options would have been as effective as the switch to olanzapine. Thus, further research is warranted.
在精神分裂症治疗中换药很常见。本研究考察了在精神分裂症患者治疗期间从利培酮进行临床必要换药后奥氮平治疗的有效性。
这项事后分析使用了一项针对精神分裂症患者的随机、开放标签、为期1年研究中利培酮组的数据。研究方案允许在临床必要时更换抗精神病药物,并采用标准的精神病学测量方法评估结果。统计分析评估了换药前后的变化,以及从利培酮换为奥氮平的患者与继续使用利培酮的患者之间的终点比较。
大多数从利培酮换药的患者换用了奥氮平(43/60;71.7%)。换药前利培酮的平均治疗时长为86天(平均模式剂量4.0毫克/天)。大多数换药者(86%)完成了为期1年的奥氮平研究(平均时长241天;平均模式剂量12.0毫克/天)。换用奥氮平后,患者在临床(简明精神病评定量表)和社会(生活质量量表)参数方面有显著改善,与无需换药的利培酮患者相比,终点时达到缓解状态的患者比例相似(41.9%对35.5%)。换药者在使用利培酮时(平均治疗时长<3个月)平均体重增加约0.4千克,在使用奥氮平时(平均治疗时长约8个月)平均体重增加2.4千克。
本研究表明,对于需要从利培酮换药的精神分裂症患者,奥氮平是一种有效的治疗选择。鉴于样本量小且缺乏对照组,无法确定其他药物选择是否与换用奥氮平一样有效。因此,有必要进行进一步研究。